Tearing off the heavy asset label, why is WuXi AppTec (02359) seeing its profits accelerate?

In the current macro context of profound changes in the global biopharmaceutical investment and financing cycle, as well as R&D demand, the CXO sector has long been stereotyped as a traditional industry characterized by heavy assets and labor intensity. Consequently, market attention often tends to focus solely on the single scale figures reported on earnings statements. However, a deep analysis of multiple financial reports from WuXi AppTec (02359) spanning from the first half of 2025 to the first half of 2026 reveals a unique phenomenon with significant industry benchmark implications the company's profit growth rate has consistently and notably exceeded the revenue growth rate during the same period, resulting in an increasingly wide scissor gap. From recent financial disclosures and performance data, since the first quarter of 2025, the difference between adjusted profit growth rate and revenue growth rate has demonstrated a high operating trend with figures of 19.02%, 27.54%, 26.96%, and 27.16%, further expanding to 44.3% in the first half of 2026. In other words, for each additional unit of revenue, the efficiency of profit creation is continually improving, indicating that the company's growth logic is steadily transitioning from mere scale expansion to value creation driven by high value-added business. From quantitative change to qualitative change, high value-added business opens up the profit growth ceiling. This leapfrogging growth is not reliant on incidental non-recurring gains but is rooted in the unique CRDMO integrated business model dividends of WuXi AppTec, deep optimization of its main revenue structure, and systematic enhancements in lean operational efficiency. It is understood that the source of WuXi AppTec's high profit margins is deeply embedded in the profound transformation of its revenue structure, particularly evident in three dimensions progressing in tandem: First, the company's distinctive "follow-molecule" strategy has officially entered the harvest phase after long-term cultivation, with the proportion of high-value projects in the overall business steadily increasing. As of the end of June 2026, the total number of small molecule D&M pipelines had reached 3,731, with commercial projects rising to 95. These projects, positioned at the backend of the value chain, often possess a higher profit contribution rate, thereby driving a structural increase in overall profit margins. Second, the TIDES business has experienced explosive growth, with revenues reaching 7.26 billion yuan in the first half of 2026, a year-on-year increase of 44.3%. The company has raised its full-year revenue guidance for this business to approximately 45% rapid growth. It currently maintains an industry-leading position in cutting-edge tracks such as nucleic acids, conjugates, multi-specific antibodies, and peptides, undoubtedly becoming the company's second growth curve for profitability. Finally, the biology + testing integrated service platform demonstrates a strong synergistic effect, bringing in over 20% new customers in the first half of 2026 and continuously supplying a vast number of high-value projects across the entire group. The ability to realize profits continues to leap, forging a cash cow level HALO asset. WuXi AppTec's overall gross margin (56.56%) and adjusted profit margin (42.36%) in the second quarter both broke historical ceilings. What does this indicate? Using its 38.36% adjusted net profit margin as a benchmark, among the A-share cohort with quarterly revenues surpassing 10 billion yuan, very few can maintain earnings at this extreme level, with the exception of financial and high-end liquor giants. Not only is it able to make money, it is also able to collect money. WuXi AppTec's ability to convert profit into free cash flow is accelerating evolution. In the first half of this year, the company's adjusted non-IFRS profit reached 11.57 billion yuan, while adjusted operating cash flow hit 9.98 billion yuan. This means that its operating cash flow accounted for an astonishing 86.25% of profit. What further excites the market is that, by the end of the second quarter, the company had over 10 billion yuan in accounts receivable on its books. Based on its approximately 55-day extremely short payment cycle, most of this hefty amount is expected to be directly converted into real cash flow net in the third quarter. As the conversion capability between profit and cash flow continues to rise, WuXi AppTec's willingness and ability to return value to shareholders are also growing. Following the release of strong mid-term financial results, the company announced its decision to implement a mid-term dividend for the second consecutive year, further expanding the dividend scale to 1.5 billion yuan. This initiative to share high-quality development results with real cash with shareholders is continuously solidifying its scarce value as a core HALO asset in the A-share market. From the ongoing expansion of the performance scissor gap, it is clear that WuXi AppTec has successfully achieved a transition from scale growth to value creation. Benefitting from the success of various client products and excellent management execution, the company has raised its full-year guidance for 2026: it expects total revenue to reach 58.5 to 60.5 billion yuan, with a continuing year-on-year growth of 35-39% in ongoing operational business revenue. Looking ahead, this high-quality development paradigm, centered on quality and propelled by technology, will continue to drive WuXi AppTec through cycles, delivering sustainable high-quality returns to shareholders and winning a higher-dimensional global competitive advantage.